Docetaxel effectively mobilizes peripheral blood CD34+ cells.

Abstract

We prospectively evaluated docetaxel (100 mg/m2) with G-CSF (10 microg/kg S.C., daily) for mobilization efficiency in 26 patients with breast cancer. The minimum target yield was >4.5 x 10(6) CD34+ cells/kg (optimum = 9 x 10(6)/kg), sufficient to support the subsequent three cycles of high-dose therapy (HDT). The peak days for peripheral blood (PB) CD34+ cells were day 8 and day 9. Seven collections began on day 7, 16 on day 8 and three on day 9. The median peripheral blood progenitor cell (PBPC) CD34+ cell content ranged from 1.2 to 5.9 x 10(6)/kg per day during days 7 to 11 with a median CD34+ content of the total 72 PBPC collections of 3.4 x 10(6)/kg (0.07-15.6). Fifteen patients obtained a PBPC collection exceeding 5 x 10(6)/kg on a single day of collection. Following a median 3 days collection for each patient (range 2-4), the median total CD34+ for all individual sets of collections was 9.7 x 10(6)/kg (range 1.0-28.4). We were able to achieve the minimum CD34+ cell target yield in 22 of 26 patients with one cycle of mobilisation chemotherapy and in two of these patients a second collection yielded sufficient cells. Twenty-two patients have subsequently received repetitive HDT and PBPC transplantation with 57 cycles of HDT having been delivered. For all 57 cycles, the median time to absolute neutrophil count (ANC) >0.5 x 10(9)/l and 1.0 x 10(9)/l was 10 days (range 8-22) and 11 days (range 8-23), respectively. The median time to platelets greater than 20 x 10(9)/l, 50 x 10(9)/l and 100 x 10(9)/l was 13 days (range 11-23), 17 days (range 12-53) and 23 days (range 18-70), respectively. We conclude that docetaxel with G-CSF effectively mobilises PBPCs with apheresis needing to be commenced approximately 8 days after docetaxel administration.

• Authors: H M Prince, G C Toner, J F Seymour, D Blakey, P Gates, S Eerhard, P Chapple, D Wall, M Quinn, S Juneja, M Wolf, E H Januszewicz, G Richardson, J Scarlett, P Briggs, M Brettell, D Rischin
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 26 Issue 5 Pg. 483-7 (Sep 2000) ISSN: 0268-3369 [Print] England
• PMID: 11019836 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, CD34
• Antineoplastic Agents, Phytogenic
• Taxoids
• Docetaxel
• Paclitaxel

Topics

• Adult
• Antigens, CD34 (blood, drug effects)
• Antineoplastic Agents, Phytogenic (administration & dosage, pharmacology, toxicity)
• Blood Component Removal (methods, standards)
• Breast Neoplasms (drug therapy)
• Cell Count
• Docetaxel
• Drug Evaluation
• Female
• Hematopoietic Stem Cell Mobilization (methods, standards)
• Hematopoietic Stem Cell Transplantation (methods, standards)
• Hematopoietic Stem Cells (drug effects, immunology)
• Humans
• Middle Aged
• Paclitaxel (administration & dosage, analogs & derivatives, pharmacology, toxicity)
• Prospective Studies
• Taxoids
• Time Factors